NEW YORK (GenomeWeb) – N-of-One said this week that it has been selected by CeGaT to interpret data from its next-generation sequencing-based oncology tests.
Under the terms of the agreement, N-of-One will analyze data from CeGaT's NGS panel which tests for more than 550 cancer genes. The company's interpretation results will include biological and clinical information about mutations found in the tumor as well as access to potential therapeutic strategies and clinical trials.
Financial and other terms of the deal were not disclosed
N-of-One's customer base includes Cedars-Sinai Medical Center. The company also has a co-marketing agreement with Appistry that allows both companies sell each other's content, technology, and services.